All stocks / ECOC
ABVC BIOPHARMA, INC. ECOC
Abvc Biopharma (ECOC): convertible notes mentioned in an 8-K in November 2026, a late 10-Q notice in May 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- ECOMINAS CORPORATION
- Market tier
- OTC Pink Current
- Trading status
- Active
- Last trade
- Nov 13
- Website
- www.ecologycoatings.com
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($7,908,554)
It spends more than it earns
Under strainThe company lost $7.9 million in the year. It reported no sales.
- Cash and cash equivalents
- $681,480
- Net cash used in operating activities
- ($2,986,299)
The cash could run out soon
Under strainIt had $681,480 in the bank and used about $248,858 a month. At that pace the money lasts about 3 months unless it borrows or sells more shares.
- Total assets
- $21,062,203
- Total liabilities
- $7,764,723
It owns more than it owes
SteadyEverything the company owns adds up to $21.1 million. Its debts and unpaid bills add up to $7.8 million. That is about $0.37 owed for every $1 owned.
What this adds up to
2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 26,976,625 shares as of 2026-11-09: 26,976,625 outstanding minus 0 held by 0 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-11-02 mentions: convertible note, equity line.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Filed NT 10-Q on 2026-05-15: notice that a periodic report is late.
Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-11-16 | S-8 | REGISTRATION STATEMENT |
| 2026-11-13 | 424B4 | PROSPECTUS SUPPLEMENT |
| 2026-11-13 | 424B4 | PROSPECTUS SUPPLEMENT |
| 2026-11-13 | 424B4 | PROSPECTUS SUPPLEMENT |
| 2026-11-13 | 424B4 | PROSPECTUS SUPPLEMENT |
| 2026-11-12 | S-3/A | AMENDMENT NO. 1 TO FORM S-3 |
| 2026-11-10 | D | |
| 2026-11-10 | 10-Q | QUARTERLY REPORT |
| 2026-11-02 | 8-K | CURRENT REPORT |
| 2026-09-29 | DEF 14A | DEFINITIVE PROXY STATEMENT |
| 2026-09-11 | PRER14A | REVISED PRELIMINARY PROXY STATEMENT |
| 2026-08-27 | 8-K | CURRENT REPORT |
Common questions about ECOC
Does ECOC file reports with the SEC?
Yes. Abvc Biopharma files with the SEC under company number 0001173313. The most recent filing we hold is a S-8 dated 2026-11-16.
Source recordHow many ECOC shares are outstanding?
26,976,625 shares as of 2026-11-09, as reported to the SEC.
Source recordHas ECOC filed reports late?
Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-Q on 2026-05-15. A notice means a report was not ready on time; check whether the report followed.
Source recordIs Abvc Biopharma making money?
The company lost $7.9 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record